We are live on ! Find out more
SCPS

Scopus BioPharma Inc. Common Stock
SCPS

Delisted

SCPS was delisted on the 16th of December, 2022.

Back to rankings

21 hedge funds and large institutions have $4.71M invested in Scopus BioPharma Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

700% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 1

313% more capital invested

Capital invested by funds: $1.14M → $4.71M (+$3.57M)

50% more funds holding

Funds holding: 14 → 21 (+7)

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

Holders
21
Holders Change
+7
Holders Change %
+50%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
5
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$6.37M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.1M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$200K
4
Morgan Stanley
Morgan Stanley
New York
+$130K
5
Two Sigma Investments
Two Sigma Investments
New York
+$92.2K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$226K
2
TRCT
Tower Research Capital (TRC)
New York
-$51.5K
3
First Manhattan
First Manhattan
New York
-$6.06K
4
HI
Harbour Investments
Wisconsin
-$1.44K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$3.43M +$6.37M +2,100,000 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$594K +$1.1M +363,041 New
BCM
3
Bridgeway Capital Management
Texas
$154K +$70K +23,100 +33%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$108K +$200K +66,121 New
Morgan Stanley
5
Morgan Stanley
New York
$72K +$130K +43,012 +4,301%
Two Sigma Investments
6
Two Sigma Investments
New York
$50K +$92.2K +30,403 New
Millennium Management
7
Millennium Management
New York
$44K -$226K -74,611 -73%
First Manhattan
8
First Manhattan
New York
$42K -$6.06K -2,000 -7%
Citadel Advisors
9
Citadel Advisors
Florida
$34K +$63.3K +20,897 New
Renaissance Technologies
10
Renaissance Technologies
New York
$34K +$63.4K +20,900 New
State Street
11
State Street
Massachusetts
$33K – – –
BlackRock
12
BlackRock
New York
$32K +$1.55K +510 +3%
VF
13
Virtu Financial
New York
$25K +$45.6K +15,031 New
Northern Trust
14
Northern Trust
Illinois
$20K +$37.9K +12,516 New
TRCT
15
Tower Research Capital (TRC)
New York
$9K -$51.5K -16,981 -75%
JP Morgan Chase
16
JP Morgan Chase
New York
$8K – – –
UBS Group
17
UBS Group
Switzerland
$8K +$14.4K +4,740 +4,740%
CLOS
18
Compagnie Lombard Odier SCmA
Switzerland
$7K – – –
HI
19
Harbour Investments
Wisconsin
$2K -$1.44K -475 -32%
Royal Bank of Canada
20
Royal Bank of Canada
Ontario, Canada
$2K – – –
Wells Fargo
21
Wells Fargo
California
– +$42 +14 +29%

SCPS Hedge Fund Activity: Q4 2021 in Review

21 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Scopus BioPharma Inc. Common Stock (SCPS) for Q4 2021, worth a combined $4.71M — up 313% from $1.14M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new SCPS positions and 1 closed out — a net gain of 7 holders — while 5 added to existing stakes and 4 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $6.37M. The largest seller was Millennium Management, cutting an estimated $226K.

  • 21 institutional investors held Scopus BioPharma Inc. Common Stock (SCPS) as of Q4 2021, up from 14 in Q3 2021.
  • Funds reported $4.71M of Scopus BioPharma Inc. Common Stock stock for Q4 2021, up 313% quarter-over-quarter.
  • 8 funds opened new Scopus BioPharma Inc. Common Stock positions in Q4 2021 and 1 closed out, a net change of +7 holders.
  • The largest Scopus BioPharma Inc. Common Stock buyer in Q4 2021 was Armistice Capital, an estimated $6.37M added.
  • The largest Scopus BioPharma Inc. Common Stock seller in Q4 2021 was Millennium Management, an estimated $226K sold.

Based on aggregated 13F filings for Q4 2021.